Want to see TRVN full AI Analyst Report?
TRVN Stock Chart & Stats
$0.02
-$0.25(-13.52%)
At close: 4:00 PM EST
$0.02
-$0.25(-13.52%)
Day’s Range― - ―
52-Week Range$0.01 - $0.91
Previous CloseN/A
Volume2.03K
Average Volume (3M)1.10K
Market Cap
$9.59K
Enterprise Value$27.01
Total Cash (Recent Filing)$13.46M
Total Debt (Recent Filing)$37.56M
Price to Earnings (P/E)―
Beta-3.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding863,788
10 Day Avg. Volume1,032
30 Day Avg. Volume1,103
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-33.45
Price to Sales (P/S)81.95
P/FCF Ratio-7.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe company announced an amendment to its royalty financing agreement with R-Bridge, bringing in $2MM in upfront cash and reducing its outstanding liabilities by $10MM.
Market RatingFocus remains on advancing TRV-045; analysts reiterate a Market Outperform rating and $3 risk-adjusted, DCF-derived price target on Trevena.
Product DevelopmentTRV045 should be an interesting asset for potential acquirors as an S1P-R1 specific modulator, with potential effectiveness in diabetic neuropathic pain and epilepsy.
Bears Say
Employment And ManagementThe company recently terminated most of its employees, including three senior managers, leaving them with only four employees.
Financial PositionBy the end of the third quarter, the company reported cash and cash equivalents of $13.5 million, which is insufficient to support the company's operation for a year.
Stock Market ListingThe company announced receiving a de-listing notice from Nasdaq, and its common stocks are now trading on the pink open market.
Trevena News
TRVN FAQ
What was Trevena Inc’s price range in the past 12 months?
Trevena Inc lowest stock price was $0.01 and its highest was $0.91 in the past 12 months.
What is Trevena Inc’s market cap?
Trevena Inc’s market cap is $9.59K.
When is Trevena Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Trevena Inc’s earnings last quarter?
Currently, no data Available
Is Trevena Inc overvalued?
According to Wall Street analysts Trevena Inc’s price is currently Overvalued.
Does Trevena Inc pay dividends?
Trevena Inc does not currently pay dividends.
What is Trevena Inc’s EPS estimate?
Trevena Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trevena Inc have?
Trevena Inc has 863,788 shares outstanding.
What happened to Trevena Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Trevena Inc?
Currently, no hedge funds are holding shares in TRVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Trevena Inc
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Technical Analysis
Scinai Immunotherapeutics
―
―
GRI Bio
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
―
Insiders
0.09% Mutual Funds
<0.01% Other Institutional Investors
99.91% Public Companies and
Individual Investors